Clinical studies on pca
Work in our department and now elsewhere has established that this lens has exceptionally low PCO rates in comparison with PMMA and silicone disc lenses. 19, 20 Three years after surgery we found areas of PCO to be 57% for PMMA, 39% for silicone and 9% for AcrySof -a highly significant result that was reflected in YAG rates of 26% for PMMA, 14% for silicone and 0 for AcrySof.21
AcrySof has other characteristics such as reduced anterior capsule fibrosis and stability of the anterior capsule on the IOL surface. 22 shown both in vitro and in animal studies (presented at ESCRS 1998) that lens epithelial cell migration is inhibited at a square edge and our own clinical studies support this. However, the edge profile will not explain the anterior capsule stability or lens epithelial cell changes. AcrySof is also unique in that the IOL has a tacky surface and Japanese work shows the capsule adheres to the implant. 25 We feel that a tight seal between the capsule and the IOL is likely to be an important additional factor in restricting access of aqueous and nutrients to the lens epithelial cells leading to cell atrophy and apoptosis.
Conclusion
The advent of AcrySof IOLs has focused commercial attention on the problems of PCO and the benefits of its prevention, and for the first time has provided a clinically effective technique that does not have side effects. It is interesting that as the mechanism of action of the lens becomes better understood research is becoming focused once again on the importance of IOL materials and design. It is highly likely that the next generation of IOLs will have inherent advantages in protecting the eye from PCO, and it is remarkable that this can be achieved without the problems of drug toxicity. The impact on cataract surgery and blindness in developing countries will be enormous.
